Cargando…
Oral hypoglycemic agents: do the ends justify the means?
BACKGROUND: Glyburide has replaced insulin as the first line of therapy in the treatment of gestational diabetes in the United States. Glyburide and metformin therapies were reported to be comparable to insulin yet also cost-effective, patient-friendly, and potentially compliance-enhancing. Recently...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823678/ https://www.ncbi.nlm.nih.gov/pubmed/27057336 http://dx.doi.org/10.1186/s40748-015-0021-6 |